Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00915278 · ClinicalTrials.gov registry record · Phase 1
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00915278 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 33 participants.
The verdict
NCT00915278, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive to standard therapies.
Interventions
- DRUG PF-04605412
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00915278
The ClinicalTrials.gov registry entry for NCT00915278 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04605412 is the first listed.
NCT00915278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00915278 about?
NCT00915278 is a clinical study titled "A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors". Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive to standard therapies.
What is the current status of trial NCT00915278?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2009-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00915278?
The interventions under investigation include: PF-04605412 (DRUG).
Who is sponsoring clinical trial NCT00915278?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.